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DNA methylation arrays as surrogate measures
of cell mixture distribution
Eugene Andres Houseman1*, William P Accomando2, Devin C Koestler3, Brock C Christensen3,
Carmen J Marsit3, Heather H Nelson4, John K Wiencke5 and Karl T Kelsey2,6
Abstract
Background: There has been a long-standing need in biomedical research for a method that quantifies the normally
mixed composition of leukocytes beyond what is possible by simple histological or flow cytometric assessments. The
latter is restricted by the labile nature of protein epitopes, requirements for cell processing, and timely cell analysis. In
a diverse array of diseases and following numerous immune-toxic exposures, leukocyte composition will critically
inform the underlying immuno-biology to most chronic medical conditions. Emerging research demonstrates that
DNA methylation is responsible for cellular differentiation, and when measured in whole peripheral blood, serves to
distinguish cancer cases from controls.
Results: Here we present a method, similar to regression calibration, for inferring changes in the distribution of white
blood cells between different subpopulations (e.g. cases and controls) using DNA methylation signatures, in
combination with a previously obtained external validation set consisting of signatures from purified leukocyte
samples. We validate the fundamental idea in a cell mixture reconstruction experiment, then demonstrate our
method on DNA methylation data sets from several studies, including data from a Head and Neck Squamous Cell
Carcinoma (HNSCC) study and an ovarian cancer study. Our method produces results consistent with prior biological
findings, thereby validating the approach.
Conclusions: Our method, in combination with an appropriate external validation set, promises new opportunities
for large-scale immunological studies of both disease states and noxious exposures.
Background
The biology of the development of any multisystem life
form is fundamentally grounded in systematic cellular
differentiation. This is essentially defined by lineage com-
mitment of cells whose origin can be traced to a pluripo-
tent progenitor and is marked by mitotically heritable
epigenetic changes that reflect complex transcriptional
programming of gene expression within the individual
cell [1-3]. One such epigenetic mark is DNA methyla-
tion, which is tightly associated with alterations in the
nucleosome DNA scaffold (and hence chromatin) that is
responsible for coordination of gene expression in indi-
vidual cells [1-3]. It is now appreciated that differentially
methylated DNA regions (DMRs) distinguish cell lineages
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with high sensitivity and specificity [4] and considerable
research is now underway to delineate precise DMRs that
define and specify a particular cell lineage. The most
developed understanding of epigenetic markers of lineage
commitment to date is perhaps that of immune cell sub-
classes defined by populations of distinct circulating blood
cells [5,6].
Pluripotent hematopoietic stem cells residing in the
bone marrow continually give rise to the entire hierarchy
of blood cell subclasses through a developmental process
known as hematopoiesis. Leukocytes, commonly called
white blood cells, are critical in the host response to
pathogens and foreign antigens and are divided into two
compartments, the myeloid lineage and lymphoid lineage
(also called lymphocytes). The composition of leukocyte
populations is well known to reflect disease states and tox-
icant exposures and can be altered by signaling cascades
that prompt migration of whole classes of cells into or out
of tissues. Several DMRs that serve as reliable biomarkers
© 2012 Houseman et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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of individual human white blood cell types have already
been identified [5,6]. Individual assays identifying cell-
specific DMRs have proven useful for quantifying indi-
vidual cell types in human tissues and peripheral blood.
However, these assays are limited to detecting the rela-
tive proportion of one individual cell type compared with
all others. On the other hand, simultaneous quantification
of fluctuation in overall lymphocyte population compo-
sition can be accomplished only by using methods based
on flow cytometry, which require large volumes of fresh
blood and involve laborious antibody tagging. Hence, an
approach that allows for the simultaneous quantification
of the entire distribution of cell types, using an array
of biomarkers based on generally available technology,
would be considerably more informative, especially in
studies of human disease and exposures.
In some instances, it is generally the overall bal-
ance of leukocyte subclasses in circulation or tissue that
most prominently influences pathogenesis. For example,
although incipient cancer cells are recognized and elimi-
nated by cytotoxic T-cells (CTLs) and natural killer (NK)
cells, tumorigenesis is also promoted by certain other
inflammatory cells, including B-lymphocytes, mast cells,
neutrophils, regulatory T-cells (Tregs), and numerous
others. All of these cells have been shown to promote
angiogenesis, tumor cell proliferation, tissue invasion and
metastasis [7,8]. Likewise, while higher levels of NK cells
and CTLs circulating in the blood and residing in adipose
tissues are associated with lower incidence of metabolic
diseases such as type II diabetes [9], higher levels of
M1 macrophages in adipose tissue can induce inflamma-
tion and insulin resistance [10]. These examples illustrate
incredible potential for methods of quantifying the com-
position of lymphocyte populations to critically inform
the underlying immuno-biology of disease states as well as
the immune response to almost all chronic medical condi-
tions. In addition, they offer great potential for predicting
therapeutic outcomes [11].
Here we employ the concept of DMRs as markers of
immune cell identity using a high density methylation
platform, and propose a set of analytical tools for esti-
mating the proportions of immune cells in unfractionated
whole blood that does not require fresh cells. The back-
bone of the approach is the DNA methylation signature
of each of the principal immune components of whole
blood (B cells, granulocytes, monocytes, NK cells, and T
cells subsets). We essentially seek a form of regression cal-
ibration, where we consider a methylation signature to be
a high-dimensional multivariate surrogate for the distri-
bution of white blood cells. In turn, this distribution is
of interest for predicting or modeling disease states. As a
surrogate, the DNA methylation signature is assumed to
be a highly correlated, yet imperfect, measure of leuko-
cyte distribution, and thus fits into the framework of
measurement error models, where the use of a noisy sur-
rogate marker to investigate an association with a disease
outcome of interest results in biased estimates, unless
internal or external validation data can be obtained to
“calibrate” the model and correct the bias [12]. However,
in this case, the problem is complicated by the extremely
high dimension of the surrogate, so we propose an alter-
native to the traditional regression-calibration procedure
that circumvents these complications but still allows us to
extract the desired biological information.
We note that since we began this work, a small number
of authors have published similar deconvolution algo-
rithms using gene expression data [13-15]. The techniques
are similar to the quadratic programming method we
describe below in Methods for deconvolving a single
sample, but none comprehensively addresses statistical
properties or employs data from DNA methylation.
Methods
In this section we describe our proposed statistical meth-
ods, the data sets used to demonstrate their utility, and
finally the design of simulation studies we have con-
ducted to investigate statistical properties of our proposed
algorithms.
Statistical methods
Let Y0h be an m × 1 vector of methylation assay values,
e.g. average beta values from an Infinium bead-array prod-
uct corresponding to a purified blood sample consisting
of a homogenous cellular population (e.g. monocytes or
granulocytes), with the qualitative characterization of cell
type (among d0 such types) indicated by a d0 × 1 covari-
ate vector wh. Here, h ∈ {1, . . . , n0}, where n0 is the
number of specimens and the m individual values corre-
spond to CpG sites on a DNA methylation microarray,
possibly pre-selected to correspond to putative DMRs
for distinguishing different cellular types. Correspond-
ingly, let Y1i be an m × 1 vector of methylation assay
values for the same CpG sites (in the same order) as
Y0h, but corresponding to a heterogeneous mixture of
cells (e.g. peripheral whole blood) from a human sub-
ject. Here, i ∈ {1, . . . , n1}, n1 is the number of target
specimens, and z1i is a d1 × 1 covariate vector repre-
senting phenotypes or exposures corresponding to the
subject, e.g. d1 = 2 for a simple case/control study
without confounders. Our goal is to understand the asso-
ciations between Y1i and z1i in terms of associations
between Y0h and w0h, i.e. to infer changes in mix-
tures of cell types associated with phenotypes or expo-
sures, using DNA methylation as a surrogate measure of
cell mixture. Thus, we have two data sets, S0 = {(Y01,
w1), . . . , (Y0n0 , wn0)}, the set of data from “purified” cell
samples effectively representing external validation or
gold-standard data, and S1 = {(Y11, z1), . . . , (Y1n1 , zn1)},
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representing surrogate data collected from a target popu-
lation. To this end, we posit the following linear models:
Y0h = B0w0h + e0h
Y1i = B1z1i + e1i,
(1)
where B0 and B1 are, respectively, m × d0 and m × d1
matrices and e0 and e1 are error vectors. For simplicity
we assume a one-way ANOVA parameterization for w,
though in the Additional file 1 we describe slight gen-
eralizations to account for design complications met in
practice. We also assume a reasonable regression param-
eterization for z, including an intercept, and for conve-
nience, denote the first column of B0 as μ1, the m × 1
intercept. The error vectors e0 and e1 may reflect indepen-
dence among arrays h and i, or else may have more com-
plex random effects structure accounting for technical
effects or biological replication; however, their substruc-
tures are incidental to this analysis, with the exception
of the fine details of the bootstrap procedure proposed
below.
To implement a surrogacy relation, we propose the
following linking regression model:
B1 = 1mγ T0 + B0 + U, (2)
where  is a d0 × d1 matrix that summarizes asso-
ciations between the rows of B0j and B1i and U is a
matrix of errors. Substituting equation (2) into (1), writing
B0 = (b01, . . . , b0d0) explicitly in terms of its columns and




b0l(γ Tl z1i) + (1mγ T0 + U)z1i + e1i. (3)
To impart a biological interpretation, we assume that the
DNA assayed in S1 arises as a mixture of DNA from
cell types profiled in S0, with mixture coefficients whose
population averages, conditional on z, are {ω(z)1 , . . . , ω(z)d0 },
so that




where the m × 1 vector ξ (z) represents cell types excluded
from consideration among the purified samples in S0, or
else non-cell-specific methylation, including alterations at
the molecular level in the maintanence of DNA methyla-
tion patterns themselves (possibly exposure related, age,
or disease related). It follows from (3) and (4) that the mix-
ture coefficients are recoverable from , ω(z)l = γ Tl z1i,
provided ξ (z) is orthogonal to the column space of B0.
As we discuss in detail in the Additional file 1, bias
can arise if differences in ξ (z) between distinct values
of z have nonzero projection onto the column space of
B0, although the magnitude of anticipated biases can be
assessed through sensitivity analysis.
It is possible to assign interpretations to the components
of variation in (3). Let SSo represents overall variability in
Y1i, i.e. SSo = ∑n1i=1 ‖Y1i−μ̄1‖2, where μ̄1 = E(Y1i). From
multivariate probability theory it is straightforward to
show that SSo = SSe+SSv+SSu, where SSe = ∑n1i=1 ‖e1i‖2,
SSv = ∑n1i=1(z1i − z̄1)TTBT0 B0(z1i − z̄1), and SSu =∑n1
i=1{(z1i − z̄1)TUTU(z1i − z̄1)+ m(z1i − z̄1)Tγ0γ T0 (z1i −
z̄1)}. SSe measures variation unexplained by the covari-
ates z1i, presumed to represent a combination of technical
noise and unsystematic biological heterogeneity. SSv mea-
sures variability explained by mixtures of profiles in the
set S0, while SSu measures variability in systematic biolog-
ical heterogeneity that nevertheless remains unexplained
by mixtures of profiles in S0, presumably due to some
process other than differences in mixtures of cell types.
Thus we propose two partial coefficient of determination
measures: R21,0 = SSv/SSo, which represents the propor-
tion of total variation in S1 explained by S0, and R21,1 =
SSv/(SSo − SSe), which represents the proportion of sys-
tematic variation in S1 explained by S0. Note that R21,1 is
poorly defined when SSo ≈ SSe.
Estimation procedes by applying an appropriate linear
model, e.g. ordinary least squares, linear mixed effects
models [16], limma [17], or surrogate variable analysis
[18,19], to obtain estimates B̂0 and B̂1. Estimates of γ0
and  are then obtained by projecting B̂1 onto the col-
umn space of B̃0 = (1m, B0), as described in detail in the
Additional file 1. Standard errors can be obtained in one
of three ways. The simplest estimator, SE0, is the “naive”
estimator from simple least-squares theory, ignoring the
fact that B̂0 and B̂1 are estimates, i.e. potentially variable.
To account for variation in estimating B̂1, a simple alter-
native is to use a nonparametric bootstrap procedure. For
each bootstrap iteration t, we sample with replacement
from S1 (or sample errors in a manner consistent with a
hierarchical experimental design) to obtain S(t)1 , produc-
ing bootstrap estimates B̂(t)1 from which “single-bootstrap”
standard errors SE1 are computed. Finally, it is possible
to account for variation in estimating B0 by also boot-
strapping S0; because of potentially small sample sizes
n0, we propose using a parametric bootstrap. A“double-
bootstrap” standard error estimator, SE2, is computed
from these two sets of bootstraps. The double-bootstrap
has the additional benefit over the single-bootstrap, in that
it can be used to assess bias due to measurement error
(variability) in B̂0. Estimation details are provided in the
Additional file 1, as are the results of simulation studies.
Beyond bias due to measurement error, which is easily
corrected using the double-bootstrap procedure, there are
additional sources of potential bias. For example, consider
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a univariate z1i representing case/control status, where
δ ≡ ξ (1) − ξ (0) = B0α for some d0 × 1 vector α = 0; i.e.
δ is the mean difference in DNA methylation between a
case and control, contributed by cell mixtures that remain
uncharacterized or non-cell-specific methylation. In such
a situation, there will be a bias equal to α in estimating
the mixture differences. The Additional file 1 provides a
detailed analysis of such biases, and proposes a sensitivity
analysis procedure for assessing the magnitude of possible
bias in a given data set.
While the focus of this paper is analysis of population
data, it is possible to use S0 to predict distribution of
leukocytes in a single sample having DNA methylation
profile Y∗. Equating the intercept term of B1 in (1) with Y∗
and applying (2), we obtain mixing proportion estimates
∗ = (B̃T0 B̃0)−1B̃T0 Y∗. Estimates can be further refined
with the use of quadratic programming techniques [20],
restricting the components of ∗, γ ∗l ≥ 0, in minimiz-
ing ‖Y∗ − B̃0∗‖2 with respect to ∗. Such individual
projections of methylation profiles on the column space
spanned by S0 facilitate the application of the fundamen-
tal ideas proposed above to individual, clinically-based
diagnostic procedures. Note, however, that DNA methy-
lation arrays are typically focused on the comparison
of methylated to unmethylated CpG dinucleotides, not
quantifying actual amounts of DNA. Therefore, informa-
tion on cell mixtures from DNA methylation is limited
to distributions, not actual counts, as one might obtain
from flow cytometry. Finally, we remark that it is possible
to model z1i directly as a function of mixture coefficients
∗ obtained individually via the constraint γ ∗l ≥ 0, but
the inferential implications are less clear, and we view the
proposed approach for populations as more statistically
robust.
Implementation
We describe several examples using existing methyla-
tion data sets as benchmarks for validating the proposed
method, in order to demonstrate its clinical or epidemio-
logical utility. First we describe the validation data set S0
used in all examples. Next we describe a laboratory recon-
struction experiment, which validates our fundamental
proposition that DNA methylation retains substantial
information about cell mixtures. Finally we describe the
results of applying our methodology to several different
target data sets S1. For the head and neck cancer and
ovarian cancer data sets, from which bead chip data were
available, a linear mixed effects model with a random
intercept for bead chip was used to estimate the cor-
responding row of B1. For the remaining data sets, no
bead chip data were available; consequently, ordinary least
squares was used. 250 bootstrap iterations were used for
each example and each of the two bootstrap methods of
standard error estimation.
Validation data
All data analyses involve DNA methylation data obtained
by the Infinium HumanMethylation27 Beadchip Microar-
rays from Illumina, Inc. (San Diego, CA). We used a
subset of m = 100 CpG sites on the array, selected as
described below. In all of our examples, S0 consisted of
46 white blood cell samples, de-identified specimens that
were not subject to human subjects review by an insti-
tutional review board (IRB). The sorted, normal, human,
peripheral blood leukocyte subtypes were purchased from
AllCells, LLC (Emeryville, CA) and were isolated from
whole blood using a combination of negative and positive
selection with highly specific cell surface antibodies con-
jugated to magnetic beads; materials and protocols were
obtained from Miltenyi Biotec, Inc. (Auburn, CA). These
46 samples are summarized in Table 1 and depicted by
the clustering heatmap in Figure 1. Note that T lympho-
cytes that express CD4 or CD8 constitute over 95% of
the T cell class, and that the pan-T cell type was fur-
ther refined to CD4+, CD8+, and “other” Pan-T cells
subtypes. In summary, the covariate vector wh consisted
of indicators for five cell types and another two indica-
tors for CD4+ and CD8+ T cell subtypes. A generaliza-
tion of the one-way ANOVA parameterization assumed
above for wh, described in the Additional file 1, was
necessary to account for the ambiguous status of some
Pan-T cells. For each CpG site, a linear mixed effects
model with a random intercept for bead chip was used
to estimate B0; 27 additional whole blood control samples
(replicates from the same individual) were used to assist
in estimating chip effects, since otherwise the data set
would have been sufficiently sparse to risk confounding
between cell type and chip. These “array controls” were
indicated with an additional term in w0h. For each CpG
site, a linear mixed effects model with a random inter-
cept for bead chip was used to estimate the correspond-
ing row of B0 and B1. From S0, F statistics (described
in the Additional file 1) were computed and used to
Table 1 Sorted white blood cells in S0
Short name Description Number
B cells CD19+ B-lymphocytes 6
Granulocytes CD15+ granulocytes 8
Monocytes CD14+ monocytes 5
NK CD56+ Natural Killer (NK) cells 11
T cells (CD4+)1,2 CD3+CD4+ T-lymphocytes 8
T cells (CD8+)1,3 CD3+CD8+ T-lymphocytes 2
T cells (NKT)1 CD3+CD56+ natural killer 1
T cells (other)1 CD3+ T-lymphocytes 5
1Considered as a member of the “pan-T-cell” group.
2Pan-T-cell further refined as also belonging to the “CD4+” group.
3Pan-T-cell further refined as also belonging to the “CD8+” group.
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Figure 1 Clustering heatmap for external validation white blood cell data (S0). Yellow = unmethylated (Yhj = 0), black = partially methylated
(Yhj = 0.5), blue = methylated (Yhj = 1).
order each of the 26,486 autosomal CpGs by decreas-
ing level of informativeness with respect to blood cell
types. As described in the Additional file 1, we deter-
mined that maximum informativeness was provided by
the top m = 100 − 300 CpG sites, with m > 300 reflect-
ing diminishing returns from adding additional CpGs.
Therefore, we chose a moderately low value in this range,
m = 100, consistent with the size of a small custom
microarray chip.
Cell mixture experiment
Proof of the utility of the proposed methods in predict-
ing leukocyte distributions for individual samples requires
extensive, detailed reconstruction experiments beyond
the scope of the present paper. However, to provide evi-
dence that such experiments are worthwhile and show
promise of positive results, we conducted a simple exper-
iment involving six known mixtures of monocytes and
B cells and six known mixtures of granulocytes and T
cells. The results of this experiment are described below
in Results.
Head and neck cancer
Our first target data set S1 consisted of arrays applied to
whole blood specimens collected in a random subset of
individuals involved in an ongoing population-based case-
control study [21] of head and neck cancer (HNSCC):
92 cases and 92 age and sex matched controls. The
study was approved by Brown University IRB, protocol
#0707992334. Blood was drawn at enrollment (prior to
treatment in 85% of the cases). Mean age among the sub-
jects arrayed in this study was 60 years, and there were
56 females and 128 males, consistent with the higher inci-
dence of the disease in men. Thus, the covariate vector z
consisted of an indicator for case/control status, an indi-
ator for male sex, and age (in decades) centered at the
mean. The clustering heatmap in Figure 2 depicts the raw
DNA methylation data in S1.
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Ovarian cancer
We next applied our method to an ovarian cancer
data set [22]. DNA methylation data for blood samples
are available from Gene Expression Omnibus (GEO,
http://www.ncbi.nlm.nih.gov/geo/, Accession number
GSE19711). We used only those cases having blood
drawn pre-treatment. After removing 4 arrays with a
preponderance of missing values, the data set consisted
of 272 controls and 129 cases having blood drawn prior
to treatment. A clustering heatmap displaying the DNA
methylation data appears in the Additional file 1. In this
analysis, z consisted of case-control status, age (catego-
rized in 5-year increments), and 2 bisulfite conversion
efficiency measures.
Down syndrome
We also applied our method to a trisomy 21 (Down syn-
drome) data set [23] consisting of 29 total peripheral blood
leukocyte samples from Down syndrome cases and 21
controls, as well as 6 T cell samples from cases and 4
T cell samples from controls (GEO Accession number
GSE25395). Because of the potential for bias induced by
copy number amplification, we excluded 4 CpG sites on
Chromosome 21, resulting in m = 96 CpG sites used
for analysis. A clustering heatmap displaying the DNA
methylation data appears in the Additional file 1. In one
analysis, we compared cases and controls using the total
leukocyte samples only, and in another we compared total
leukocytes to T cells, pooling cases and controls. The
Additional file 1 presents coefficient estimates.
Obesity in African Americans
Finally, we applied our method to an obesity data set
[24] consisting of 7 lean African-Americans and 7 Obese
African-Americans (GEO Accession number GSE25301).
A clustering heatmap displaying the DNA methylation
data appears in the Additional file 1. In this analysis, z
consisted of obesity status.
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Additional analyses
If the subject population for which z = 0 is sufficiently
homogeneous with respect to blood cell distribution to
admit sensible characterization of that distribution, then
it is possible to recover estimates from ̂. The Additional
file 1 reports the results of such an analysis applied to the
HNSCC case/control data set. Finally, we conducted an
additional analysis where we took S0 to consist of only
samples with pure CD4+ or CD8+ cells and S1 to consist
only of samples having the less purified T-lymphocytes.
For such S1, there were no covariates, so z consisted only
of an intercept.
Simulations
We conducted extensive simulation studies in order
to verify the finite-sample statistical properties of our
proposed methodology. Simulation parameters were
obtained from the HNSCC data set, and most simulations
assumed no sources of biological bias (DNA methylation
changes arising from processes not mediated by the pro-
filed leukocytes, including shifts in distribution within cell
types not profiled). In every simulation, we specified S0
to consist of 5 B-cell samples, 10 granulocyte samples,
5 monocyte samples, 15 NK samples, 5 general “Pan-T”
T-cell samples, 8 specific CD4+ T cell samples, and 2 spe-
cific CD8+ T cell samples. Estimates from the external
validation set S0, described above, were used for mean
methylation profiles among WBC types, using the m =
100 most informative CpG sites.
We specified n1/2 cases and n0/2 controls, n0 ∈
{100, 200, 500}. Among the controls, methylation profiles
were generated by a white blood cell population of 7% B-
cells, 62% granulocytes, 6% monocytes, 2% NK cells, and
13% were T-cells, of which 65% were CD4+ cells and 35%
were CD8+ cells, and the remaining 5% were unspecified
(and assumed to have mean methylation equal to that of
the unsorted T-lymphocytes). Among cases, we specified
one of the following scenarios: a 4% reduction in CD4+
cells, a 2% reduction in CD8+ cells, and an 8% increase in
granulocytes (alternative with changes in both CD4+ and
CD8+, “Strong Alternative I”); a 6% reduction in CD4+
cells, and an 8% increase in granulocytes (alternative with
changes in CD4+ but not CD8+, “Strong Alternative II”);
a weaker alternative with half the effects of Strong Alter-
native I (“Mixed Alternative” elaborated upon below); and
two null scenarios with no changes in cell population,
each with a different assumption about δ. Note that these
changes reflect absolute changes in percentage points, not
relative changes. Note also that these values were actually
used to generate Dirichlet-distributed mixture weights for
each simulated subject, with Dirichlet parameters equal
to a precision parameter (100 corresponding to “precise”
and 10 corresponding to“noisy”) times the mean weight
described above. Residual effects ξ (0)i for controls were
set equal to 0.1 times estimated intercept estimate μ̂1
obtained from the HNSCC data set, while residual effects
ξ
(1)
i for cases were set equal to 0.08 or 0.09 times μ̂1 plus
multiples 10θ of the column of Û corresponding to case.
The constants of proportionality 0.1, 0.08, and 0.09 were
chosen to correspond to assumed contributions of ξ to an
overall methylation signature presumed to be dominated
by profiled populations of white blood cells in specified
proportions, with 0.08 used for the strong alternatives and
0.09 used for the Mixed Alternative. The constant 10 was
used to amplify the scale of δ so that its effect could be
detected in simulation; note that Û was orthogonal to the
white blood cell profiles, by construction. The multiplier
θ = 0 was used for strong alternatives, and the “Strong
Null” case (i.e. no methylation differences between cases
and controls) while θ = 0.5 was used for the Mixed
Alternative, and θ = 1 was used for the “Mixed Null”
with case/control differences not mediated by cellular
population differences. A simple normal error structure
for e0h and e0i was specified, with no chip effects, but with
variance equal to the sum of chip and residual variance
estimated (individually for each CpG) for the HNSCC
data. For each simulation, 50 bootstraps were used to
estimate standard errors. 1000 simulations were run for
each scenario.
Results
In this section we report the results of the data analyses
described above in Implementation, as well as the results
of our simulation experiments.
Cell mixture experiment
As Figure 3 suggests, accuracy is within 10%, and often
less than 5%, with the largest errors occuring for gran-
ulocytes, as shown in Table 2. Note that the sum of the
individual observed predictions for each individual pro-
file ranged from 98.9% to 102.7% (data not shown), even
though the constraints of the projection do not explicitly
constrain the sum to 100%; this provides additional evi-
dence that the DNA methylation profile captures a great
deal of information about cell mixtures.
Head and neck cancer
Table 3 presents coefficient estimates ̂ for case status,
double-bootstrap bias estimates (estimates of bias aris-
ing from measurement error), as well as naive, single-
bootstrap, and double-bootstrap standard error estimates.
Each of these quantities is measured in percentage
points (%). Estimates of bias arising from measurement
error (i.e. substituting estimated quantities for known
ones in a two-stage statistical procedure) were almost
always less than half a percentage point, and for signif-
icant coefficient estimates, always towards the null. The
proportion of CD4+ T-lymphocytes decreased in cases
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Figure 3 Results of cell mixture reconstruction experiments validating prediction of individual profiles. Expected and observed
percentages of each cell type are shown by color (red=100, white=0) and text. Median root-mean-square-error over 12 samples had a median value
of 8.2%, ranging from 5.4% to 11.6%.
compared with controls, with a bias-corrected estimate of
−10.4 percentage points and approximate 95% confidence
interval (−13.1%, −3.3%); the proportion of NK cells
decreased, with a bias-corrected estimate of -1.5 percent-
age points and 95% confidence interval (−2.2%, −0.75%);
and the proportion of granulocytes increased, with a bias-
corrected estimate of 7.6 percentage points and 95% con-
fidence interval (4.2%, 10.9%). There was also somewhat
weaker evidence of an increase in CD8+ T-lymphocytes,
with an estimate of 4.5 percentage points and 95% con-
fidence interval (2.0%, 7.0%). As reported in the com-
plete set of results appearing in the Additional file 1,
the proportion of CD4+ T-lymphocytes decreased by
3.3 percentage points (−4.4%, −2.2%) per decade of age,
while CD8+ T-lymphocytes increased by 2.0 percentage
point (1.0%, 3.0%) per decade. All other coefficients were
insignificant.
For this analysis, R21,0 was estimated at 14.2%,
while R21,1 was estimated at 93.9%. Thus, a small but
non-negligible proportion of total variation (systematic
variation + unexplained biological heterogeneity + tech-
nical noise) appeared to be driven by changes in cell
population between cases and controls and as a result of
aging. Note that SSe comprised 85% of total variation, so
a substantial portion of variability in DNA methylation
appeared to remain unexplained (presumably due, in
large part, to technical noise). However, almost all of the
systematic variation appeared to be explained by changes
in cell population.
These results were consistent with previous studies, as
HNSCC patients are known to display an absolute and rel-
ative increase in myeloid derived granulocytes [25] while
also displaying an alteration in lymphoid T-cell homeosta-
sis that leads to decreases in CD4+ T-cells [26,27]. In addi-
tion, the proportion of Treg cells (a subclass of CD4+ T
cells) is known to decrease from infancy to adulthood [28].
The bias estimates obtained from the double-bootstrap
procedure allow the correction of bias arising from
Table 2 Summary statistics for errors in cell mixture
reconstruction results*
B cell Granulocyte Monocyte NK T cell
minimum 0.0 0.3 0.0 0.0 0.0
median 0.1 6.5 1.1 2.1 0.3
maximum 5.5 10.0 4.1 6.4 5.3
*|Observed% − Expected%|.
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Table 3 Estimates for HNSCC analysis (case vs. control)
Est Bias2 SE0 SE1 SE2 P-value
(Intercept, γ0) −0.62 −0.02 0.41 0.52 0.52 0.23
B Cell −0.45 0.04 0.30 0.77 0.76 0.55
Granulocyte 7.51 −0.07 0.50 1.73 1.71 <0.0001
Monocyte 0.49 0.10 0.50 0.47 0.48 0.31
NK −1.43 0.06 0.56 0.37 0.38 0.00017
T Cell (cd4+) −9.08 1.32 1.95 1.15 1.39 <0.0001
T Cell (cd8+) 3.06 −1.46 1.96 0.98 1.27 0.016
Est = Regression coefficient estimate (× 100%).
Bias2 = Double-bootstrap bias estimate (× 100%).
SE0 = Naive standard error (× 100%).
SE1 = Single-bootstrap standard error (× 100%).
SE2 = Double-bootstrap standard error (× 100%).
P-values were computed using SE2.
measurement error. However, there is no statistical pro-
cedure for correcting the other possible sources of bias,
those arising from changes in distribution among unpro-
filed cell types as well as non-immune-mediated methyla-
tion differences. The Additional file 1 presents a detailed
sensitivity analysis, from which we show that the magni-
tude of the resulting bias is likely to be small, less than a
percentage point.
Ovarian cancer
Table 4 presents results for case-control status, with
the remaining results appearing in the Additional file 1.




Compared with controls, cases showed significant
increases in granulocytes and significant decreases in B
cells, NK cells, and CD4+ T cells. Cases also showed
marginally significant increases in monocytes. These
results are consistent with previous literature, where
Table 4 Estimates for ovarian cancer analysis (case vs.
control)
Est Bias2 SE0 SE1 SE2 P-value
(Intercept, γ0) −0.05 −0.05 0.41 0.19 0.20 0.81
B Cell −1.36 0.02 0.29 0.22 0.23 <0.0001
Granulocyte 8.97 −0.04 0.49 1.02 1.00 <0.0001
Monocyte 0.55 0.06 0.49 0.29 0.30 0.066
NK −2.09 0.01 0.55 0.31 0.34 <0.0001
T Cell (cd4+) −5.64 0.18 1.93 1.06 1.34 <0.0001
T Cell (cd8+) −0.35 −0.17 1.93 0.95 1.19 0.77
Est = Regression coefficient estimate (× 100%).
Bias2 = Double-bootstrap bias estimate (× 100%).
SE0 = Naive standard error (× 100%).
SE1 = Single-bootstrap standard error (× 100%).
SE2 = Double-bootstrap standard error (× 100%).
P-values were computed using SE2.
it has been demonstrated that ovarian cancer patients
experience decreases in B and T lymphocytes [29-31],
increases in monocytes [29,30] and (somewhat equivo-
cally) increases in eosinophil granulocytes [30]. Addition-
ally, there were significant systematic decreases in CD4+
T cells with increasing age, with a gradient consistent
in direction and somewhat consistent in magnitude with
the corresponding effect found in the HNSCC data set.
Though most of the CD8+ T cell coefficients for age were
not significant, they were all positive, with gradient con-
sistent in direction and somewhat consistent in magnitude
with the corresponding effect found in the HNSCC data
set. As reported in the Additional file 1, no bisulfite
conversion coefficient was significant, and all coefficients
were of small magnitude (generally less than 1 percentage
point per standard deviation).
Down syndrome
The only significant difference between cases and controls
was in B cell distribution, with bias-corrected estimated
decrease of 4.8%, 95% confidence interval (−6.2%, −3.5%).
This result is consistent with known immune characteris-
tics of Down Syndrome, including deficiencies in both B
and T cells [32,33]. However, in the comparison between
total leukocytes and T cells, all coefficients except B Cell
and NK were highly significant, in directions consistent
with comparison of a sample of purified T cells to a generic
whole blood sample. In fact, an estimate of the cellu-
lar composition of the T cell samples can be obtained
by a simple linear transformation of  estimates (adding
intercept terms with the T cell coefficients); this oper-
ation produces values that are not significantly distinct
from zero for all cell types except CD4+ and CD8+, whose
bias-corrected estimates were, respectively, 75.9%, 95%
confidence interval (67%, 85%) and 8.6%, 95% confidence
interval (0%, 17%), consistent with the known distribution
of these T cells. For the analysis of case vs. control within
total leukocytes, R21,0 was estimated at 4.5%, while R
2
1,1
was estimated at 67.6%. For the analysis of total leukocyte
vs. T cell with pooled cases and controls, R21,0 was esti-
mated at 81.4%, while R21,1 was estimated at 98.9%. The
latter set of coefficients of determination indicate that a
substantial portion of variation is explained by composi-
tion of leukocytes, which is the expected result for such an
analysis.
Obesity in African Americans
Obese subjects had an estimated increase of 12 per-
centage points in granulocytes, bias-corrected 95% con-
fidence interval (3.4%, 20%) and an estimated decrease
of 4 percentage points in NK cells, bias-corrected 95%
confidence interval (−7.7%, −0.9%). No significant differ-
ences were found for other blood cell types. Note that
the specific immunological differences estimated by the
Houseman et al. BMC Bioinformatics 2012, 13:86 Page 10 of 16
http://www.biomedcentral.com/1471-2105/13/86
method are consistent with known immunological pertur-
bations associated with type II diabetes [9,10]. Complete
results are provided in the Additional file 1.
Additional analyses
We obtained the following unnormalized bias-corrected
estimates: 69.0% CD4+, 95% CI (54%, 84%), and 32.5%
CD8+, 95%CI (19%, 46%). This is consistent with known
proportions of these specific cell types among T
lymphocytes.
Results of simulations
Table 5 presents results for n1 = 200 with precise mix-
ture weights (small within-status heterogeneity in dis-
tribution), while Table 6 presents results for n1 = 200
with noisy mixture weights (larger within-status het-
erogeneity). The tables show mean estimate, simula-
tion standard deviation, median estimates for the three
types of proposed standard errors, and proportion of
p-values (obtained from z-scores constructed using the
double-bootstrap standard error) falling below α = 0.05
and α = 0.01. In all cases, the bias in estimation was
negligible. Both bootstrap procedures produced similar
standard error estimates, which were close to the simu-
lation standard deviation but often quite different from
the naive standard error estimate. Under null scenar-
ios, the rejection probabilities were tolerably close to
their nominal values, and for alternatives, power could
be quite high, even with this modest design. Results
for the coefficients of determination are provided in
the Additional file 1. Scenarios with n1 ∈ {100, 500} pro-
duced similar results, with simulation standard deviations
and power adjusted accordingly, but still having practical
utility.
Discussion
In this paper, we employ the concept of DMRs as markers
of immune cell identity using a high density methyla-
tion platform, and propose a set of analytical tools for
estimating the proportions of immune cells in unfrac-
tionated whole blood. The backbone of the approach is
the DNA methylation signature of each of the principal
immune components of whole blood (B cells, granulo-
cytes, monocytes, NK cells, and T cells subsets). The
examples we have provided above serve to illustrate
that our proposed methodology produces parameter esti-
mates consistent with the literature, thus validating its
utility.
Our proposed method resembles regression calibration,
where we consider a methylation signature to be a high-
dimensional multivariate surrogate for the distribution of
white blood cells. In turn, this distribution is of interest
for predicting or modeling disease states. As a surrogate,
the DNA methylation signature is assumed to be a highly
correlated, yet imperfect, measure of leukocyte distribu-
tion, and thus fits into the framework of measurement
error models, where the use of a noisy surrogate marker to
investigate an association with a disease outcome of inter-
est results in biased estimates, unless internal or external
validation data can be obtained to “calibrate” the model
and correct the bias [12]. However, in this case, the prob-
lem is complicated by the extremely high dimension of the
surrogate. Measurement error problems are typically for-
mulated as a set of relationships between z, the disease
outcome (e.g. case/control status), ω, the gold standard
(e.g. leukocyte distribution), and Y, the surrogate (e.g.
DNA methylation). Of interest is E(z|ω), which may be
difficult to estimate due to the cost or logistical com-
plications involved in obtaining ω in a large number
of samples. Typically, it is possible to collect sufficient
data for modeling E(z|Y), which provides information
about E(z|ω) through the (often imperfect) association
E(Y|ω), which is inferred from an external validation sam-
ple [12,34]. Unfortunately, the high-dimensional nature
of Y renders E(z|Y) difficult to formulate. While multi-
variate methods of measurement error correction exist,
even in a high-dimensional context [35], they require an
explicit specification of E(z|Y), requiring a large num-
ber of parameters even for a main effects regression
model, and many more in order to account for interac-
tions. This becomes unwieldy when each component of
Y contributes a small amount of information about z,
and both dimension-reduction strategies and constrained
regression strategies entail substantial loss of information
and may be extremely computationally intensive. Exist-
ing measurement error formulations [34,35] would have
required us to specify a logistic regression model for
case/control status, conditional on DNA methylation sig-
nature, a computationally difficult task that would have
extreme vulnerability to model mis-specification. On the
other hand, our method requires specification of E(Y|z),
which is natural and straightforward. Note that in some
treatments of regression calibration, E(ω|Y) is used as a
surrogate for ω in regression models for z [12]; our treat-
ment essentially assumes a linear form for E(Y|ω) and
effectively obtains E(ω|Y) by projecting Y onto the col-
umn space of resulting matrix. We note that it is possible
using existing methods to qualitatively describe immune
response contributions to DNA methylation. This is typ-
ically done by conducting a pathway analysis along the
lines of one of the methods described in [36], the best
option of which is Gene Set Enrichment Analysis (GSEA)
[37]. For example, Teschendorff et al. (2009) [22] use
GSEA to qualitatively motivate an immunological expla-
nation. However, these methods do not directly quantify
the immunological contribution.
An important consideration in the measurement error
literature is that of transportability of model parameters
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Table 5 Simulation Results (Precise Mixtures, n1 = 200)
Strong Alternative I (θ = 0)
Truth Est SD SE0 SE1 SE2 pow(0.05) pow(0.01)
B Cell 0.0 0.07 1.00 0.92 0.97 0.98 0.057 0.018
Granulocyte 8.0 8.02 0.73 0.39 0.73 0.73 1.000 1.000
Monocyte 0.0 0.01 0.48 0.43 0.47 0.47 0.055 0.013
NK 0.0 −0.09 1.08 1.02 1.02 1.05 0.066 0.015
T Cell (cd4+) −4.0 −4.06 0.81 0.80 0.78 0.81 0.999 0.989
T Cell (cd8+) −2.0 −1.93 0.83 0.81 0.78 0.81 0.653 0.419
Strong Alternative II (θ = 0)
Truth Est SD SE0 SE1 SE2 pow(0.05) pow(0.01)
B Cell 0.0 0.00 0.97 0.92 0.97 0.99 0.048 0.016
Granulocyte 8.0 8.00 0.71 0.39 0.72 0.72 1.000 1.000
Monocyte 0.0 0.03 0.48 0.42 0.47 0.47 0.063 0.016
NK 0.0 0.03 1.04 1.02 1.01 1.05 0.052 0.014
T Cell (cd4+) −6.0 −5.83 0.76 0.80 0.77 0.80 1.000 1.000
T Cell (cd8+) 0.0 −0.22 0.81 0.81 0.80 0.81 0.064 0.014
Mixed Alternative (θ = 0.5)
Truth Est SD SE0 SE1 SE2 pow(0.05) pow(0.01)
B Cell 0.0 −0.02 1.02 1.10 0.96 0.98 0.065 0.011
Granulocyte 4.0 3.99 0.75 0.47 0.73 0.73 1.000 0.995
Monocyte 0.0 0.02 0.49 0.51 0.47 0.47 0.060 0.015
NK 0.0 0.04 1.05 1.22 1.01 1.04 0.054 0.009
T Cell (cd4+) −2.0 −2.07 0.82 0.96 0.79 0.83 0.695 0.471
T Cell (cd8+) −1.0 −0.95 0.82 0.96 0.78 0.82 0.203 0.082
Mixed Null (θ = 1)
Truth Est SD SE0 SE1 SE2 pow(0.05) pow(0.01)
B Cell 0.0 0.00 1.04 1.58 0.96 1.02 0.066 0.017
Granulocyte 0.0 0.03 0.73 0.67 0.74 0.74 0.055 0.014
Monocyte 0.0 −0.01 0.47 0.73 0.47 0.48 0.054 0.013
NK 0.0 −0.01 1.12 1.76 1.01 1.09 0.063 0.014
T Cell (cd4+) 0.0 0.01 0.87 1.38 0.80 0.90 0.054 0.013
T Cell (cd8+) 0.0 −0.02 0.88 1.39 0.79 0.89 0.057 0.015
Strong Null (θ = 0)
Truth Est SD SE0 SE1 SE2 pow(0.05) pow(0.01)
B Cell 0.0 −0.01 0.99 0.90 0.96 0.96 0.068 0.014
Granulocyte 0.0 0.03 0.72 0.38 0.74 0.73 0.052 0.013
Monocyte 0.0 −0.01 0.47 0.42 0.47 0.47 0.055 0.013
NK 0.0 −0.01 1.06 1.00 1.01 1.02 0.059 0.020
T Cell (cd4+) 0.0 0.00 0.81 0.78 0.80 0.82 0.054 0.013
T Cell (cd8+) 0.0 −0.01 0.81 0.79 0.79 0.80 0.054 0.015
Est = Men regression coefficient estimate (× 100%); SD = SD regression coefficient estimate (× 100%).
SE0 = Naive standard error (× 100%); SE1 = Single-bootstrap standard error (× 100%).
SE2 = Double-bootstrap standard error (× 100%).
pow(α) = Pr{P2 < α}, where P2 is the p-value computed from SE2 .
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Table 6 Simulation Results (Noisy Mixtures, n1 = 200)
Strong Alternative I (θ = 0)
Truth Est SD SE0 SE1 SE2 pow(0.05) pow(0.01)
B Cell 0.0 −0.06 1.39 0.92 1.36 1.34 0.065 0.019
Granulocyte 8.0 7.87 2.02 0.39 2.00 1.99 0.974 0.897
Monocyte 0.0 0.05 1.03 0.42 1.04 1.02 0.049 0.012
NK 0.0 −0.02 1.21 1.02 1.16 1.18 0.061 0.010
T Cell (cd4+) −4.0 −4.00 1.23 0.79 1.21 1.22 0.903 0.739
T Cell (cd8+) −2.0 −1.97 1.05 0.80 1.02 0.98 0.517 0.298
Strong Alternative II (θ = 0)
Truth Est SD SE0 SE1 SE2 pow(0.05) pow(0.01)
B Cell 0.0 −0.08 1.38 0.92 1.36 1.34 0.063 0.017
Granulocyte 8.0 7.90 2.03 0.39 1.99 1.98 0.973 0.905
Monocyte 0.0 0.10 1.07 0.42 1.04 1.02 0.054 0.019
NK 0.0 0.02 1.17 1.02 1.14 1.18 0.053 0.009
T Cell (cd4+) −6.0 −5.70 1.19 0.80 1.13 1.16 0.999 0.986
T Cell (cd8+) 0.0 −0.23 1.08 0.81 1.10 1.04 0.066 0.015
Mixed Alternative (θ = 0.5)
Truth Est SD SE0 SE1 SE2 pow(0.05) pow(0.01)
B Cell 0.0 0.05 1.42 1.10 1.34 1.34 0.066 0.016
Granulocyte 4.0 4.00 2.01 0.47 2.02 2.01 0.500 0.291
Monocyte 0.0 0.01 1.06 0.51 1.03 1.02 0.072 0.020
NK 0.0 −0.02 1.24 1.22 1.13 1.16 0.064 0.013
T Cell (cd4+) −2.0 −2.11 1.30 0.95 1.26 1.28 0.391 0.191
T Cell (cd8+) −1.0 −0.94 1.08 0.96 1.05 1.02 0.163 0.052
Mixed Null (θ = 1)
Truth Est SD SE0 SE1 SE2 pow(0.05) pow(0.01)
B Cell 0.0 0.06 1.41 1.59 1.36 1.37 0.062 0.016
Granulocyte 0.0 0.04 2.08 0.67 2.06 2.05 0.056 0.008
Monocyte 0.0 −0.02 1.05 0.73 1.03 1.03 0.058 0.020
NK 0.0 0.01 1.26 1.76 1.14 1.22 0.066 0.011
T Cell (cd4+) 0.0 −0.01 1.42 1.38 1.31 1.36 0.067 0.016
T Cell (cd8+) 0.0 0.00 1.19 1.39 1.08 1.10 0.073 0.011
Strong Null (θ = 0)
Truth Est SD SE0 SE1 SE2 pow(0.05) pow(0.01)
B Cell 0.0 0.06 1.37 0.91 1.36 1.32 0.065 0.017
Granulocyte 0.0 0.03 2.07 0.38 2.06 2.05 0.055 0.009
Monocyte 0.0 −0.02 1.04 0.42 1.03 1.02 0.057 0.021
NK 0.0 0.01 1.19 1.01 1.14 1.16 0.053 0.018
T Cell (cd4+) 0.0 −0.04 1.38 0.79 1.31 1.31 0.069 0.015
T Cell (cd8+) 0.0 0.01 1.11 0.79 1.08 1.03 0.065 0.016
Est = Mean regression coefficient estimate (× 100%); SD = SD regression coefficient estimate (× 100%).
SE0 = Naive standard error (× 100%); SE1 = Single-bootstrap standard error (× 100%).
SE2 = Double-bootstrap standard error (× 100%).
pow(α) = Pr{P2 < α}, where P2 is the p-value computed from SE2 .
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[38]. In our setting, an important consideration is whether
the methylation profiles obtained from the purified blood
cells used to assemble S0 would be representative of the
white blood cells measured within S1. Because of the bio-
logical assumptions inherent in the DMR literature and
underlying current understanding of hematopoeisis and
lineage commitment, this assumption is reasonable, pro-
vided our method is used to detect abnormal mixtures
of normal white blood cells. However, methylation abnor-
malities in the white blood cells themselves constitute a
form of non-cell mediated alteration (in the sense of the
term we have been using), and contribute to bias in our
methods, as described briefly above and in detail in the
Additional file 1.
Note that our formulation respects the study design
(DNA methylation assay data collected after sampling
from phenotype groups). An alternative strategy out-
side the measurement error literature but within the
larger missing-data literature might have been the
use of an Expectation-Maximization (EM) algorithm
to integrate over the missing data ω [39]. However,
by design, the distribution of ω varied substantially
between the data sets S0 and S1, severely complicat-
ing the approach; notably, an would be the introduc-
tion of feedback from S1 to S0, contaminating the
gold-standard status of S0. An alternative, might be
the use of an empirical Bayes procedure, reminiscent
of existing mixture-model approaches [40]. However,
difficulty in specifying the distribution of “remainder
terms” (denoted as ξ above) render this approach unten-
able, and in simulations (not presented), attempts to
impute ω among S1 samples using parameters obtained
from S0 samples resulted in extremely biased estimates
of ω.
The most significant aspect of the current study is
our development of a method for inferring changes in
the distribution of white blood cell types between dif-
ferent human populations (e.g. cases and controls) using
DNA methylation signatures; an approach guided by an
external validation set consisting of methylation profiles
from purified white blood cell components. DNA methy-
lation in peripheral blood is a potentially powerful new
biomarker for clinical and epidemiological investigation.
By example, numerous studies have now attempted to dis-
tinguish cancer cases from controls using whole periph-
eral blood assayed via DNA methylation arrays, including
ovarian [22], bladder [41], and pancreatic [42] cancers.
While these studies have demonstrated good to excel-
lent discrimination of cases from controls, sound evidence
for a biological mechanism has been elusive. Presum-
ably, disease associated alterations in blood methylation
have several etiological components driven by inherent
genetic, environmental and disease specific factors. Given
the known developmental associated differences in DNA
methylation among specific blood cell types, changes in
the distributions of blood cell types alone could account
for disease associated DNA methylation. While numer-
ous authors provide a qualitative discussion that includes
the possibility of immune-related DNA methylation dif-
ferences (e.g.[22]), none to date has specifically quantified
the contribution from immune response. On the other
hand, the many diverse types of immune cells in blood
make this issue highly complex and problematic to tackle
using single cell type assays. Therefore, it is crucial to the
development of this new avenue of biomarker research to
delineate effects due to the immune cell distribution itself
from other “non cell type” alterations in DNA methyla-
tion. We term the differences among human populations
attributed to cell distributions to be “immunologically
mediated”. Our solution to partition this component of
variation in methylation from other determinants are
multivariate analytic tools including regression coeffi-
cients and associated inference, as well as coefficients of
determination measures. Taken together these provide a
means for evaluating whether the observed DNA methy-
lation differences are due to an immunologically mediated
response.
In our Additional file 1 we provide a detailed analysis of
potential sources of bias in our analysis. One obvious bio-
logical source of bias is age of the subjects contributing
cells for validation. At certain CpG loci, DNA methyla-
tion is known to change with age [43], especially in T
cells [44]. In the Additional file 1 we demonstrate that
any age-related associations with DNA methylation in our
top 100 CpGs were too weak to be detected with the cur-
rent validation sample, and thus unlikely to bias the results
of our analyses (notably age coefficients provided for the
HNSCC example). However, we remark that with larger
sample sizes, adjustments for age can be incorporated
with an appropriate additional term in the linear model (1)
for Y0h.
Similar methods based on mRNA have been employed
[13-15]. The statistical principles described in this arti-
cle would apply, wholesale, to mRNA expression profiles,
but with two cautionary statements. The first is math-
ematical: mRNA is typically analyzed on a logarithmic
scale, yet the assumptions of the proposed methodology
involve linearity on an arithmetic scale, since the mix-
ing coefficients are assumed to act linearly on absolute
numbers of nucleic acid molecules; thus, the proposed
methods would require analysis of untransformed fluores-
cence intensities, whose skewed distributions would result
in numerical instabilities. The second is biological: there
is no necessarily linear relationship between cell number
and mRNA copies, since proteins may be translated as
a consequence of an initial burst of mRNA transcription
upon cellular development, after which significant mRNA
degradation is possible. In contrast, one would expect
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the average beta value provided by Illumina bead-array
products (and similar quantities) to scale in proportion to
the actual fraction of methylated nucleic acids; in addi-
tion, an assumption of two DNA molecules per cell seems
biologically reasonable. In the Additional file 1 we pro-
vide an example of an application of our methods using
mRNA data.
Going forward there are two issues that require further
experimental and analytical refinement. First, although
the current studies suggest group level comparisons
of blood cell DNA methylation can reveal important
immune alterations, it will be important to provide
methods for individual level immune cell profiling, since
clinical and detailed analytical epidemiologic applications
that examine individual risk factor information will be the
subject of future studies. As we have demonstrated above,
individual immune profiles are theoretically achievable
but will require extensive validation, with a wide array of
mixture combinations, before gaining widespread accep-
tance. Secondly, there is intense interest in minor immune
cell fractions and their role in disease, though the signal
strength of cell types comprising < 5% of the total white
cell compartment may be difficult to quantitate. Exam-
ples of such cell types include the regulatory T-cell or NK
cell fractions, which are implicated in autoimmune and
malignant diseases. Optimization of platforms for tech-
nical sensitivity to minor subtypes combined with statis-
tical optimization of signature recognition are needed to
enhance the approach for testing highly targeted immune
hypotheses.
Conclusions
The method we present here has potentially far reaching
implications for rapid, simple and complete assessment
of the composition of human white blood cell popula-
tions, i.e. the immune profile. Currently, assessment of
the cellular composition of peripheral blood cannot be
accomplished without the use of freshly drawn venous
blood that is immediately prepared in a specially equipped
laboratory. A complete assessment of the entire immune
profile requires extensive flow cytometric measurements
based on protein epitopes on leukocyte membranes that
distinguishes subtypes of immune cells that are either too
rare or too similar in appearance to be distinguished using
simple microscopic approaches. In particular, flow cytom-
etry is limited by the following: (i) cells must be separated,
requiring large volumes of fresh cells; (ii) detection can
be accomplished only by the fluorescent antibody tags
available, which require expensive technology to read; (iii)
the outer cell membrane must be intact, mandating lim-
ited utility in many instances (particularly in research).
In contrast, our method requires the application of these
labor-intensive or expensive steps only in the construc-
tion of the validation set S0, which need only be developed
once. Once S0 is available, subsequent interrogation is
based on the chemically stable CpG methylation of DNA;
thus our method obviates the need for fresh blood and
the preservation of labile protein epitopes. It is also able
to simultaneously assess all of the individual components
of the peripheral blood using a highly multiplexed molec-
ular platform and is thus very straightforward logistically.
Furthermore, the statistical methodology presented here
can be implemented easily with the instrumental output
of the methylation arrays, which simplifies the interpreta-
tion of the immune profile data from the operators point
of view. This method can be immediately deployed in
a research framework to cost effectively assess human
immune profiles (in fresh or archival samples), exploring
their potential as biomarkers, and addressing key ques-
tions regarding disease pathogenesis. Furthermore, our
approach is readily suited for rapid translation to a broad
base of clinical applications such as disease monitoring,
diagnosis, prognosis, and response to therapy.
Our approach makes research on biobanked specimens
possible, now making a vast array of prospective studies
that could not otherwise be done, possible. Software and
sample data are provided in Additional file 2.
Additional files
Additional file 1: Houseman-WBC-BMCBioinformatics-
Supplement.pdf. Additional theoretical details, simulation descriptions
and results, and additional figures and result tables [43-52].
Additional file 2: Houseman-WBC-BMCBioinformatics-Software-v2.
Sample R software (compressed).
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